171 related articles for article (PubMed ID: 29855074)
21. CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients.
Satoh S; Saito M; Inoue T; Kagaya H; Miura M; Inoue K; Komatsuda A; Tsuchiya N; Suzuki T; Habuchi T
Eur J Clin Pharmacol; 2009 May; 65(5):473-81. PubMed ID: 19125240
[TBL] [Abstract][Full Text] [Related]
22. Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study.
Wang L; Li N; Wang MX; Lu SC
Genet Mol Res; 2015 Apr; 14(2):3191-9. PubMed ID: 25966085
[TBL] [Abstract][Full Text] [Related]
23. Effects of donor-recipient combinational CYP3A5 genotypes on tacrolimus dosing in Chinese DDLT adult recipients.
Liu J; Chen D; Yao B; Guan G; Liu C; Jin X; Wang X; Liu P; Sun Y; Zang Y
Int Immunopharmacol; 2020 Mar; 80():106188. PubMed ID: 31931373
[TBL] [Abstract][Full Text] [Related]
24. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
Liu LS; Li J; Chen XT; Zhang HX; Fu Q; Wang HY; Xiong YY; Liu S; Liu XM; Li JL; Huang M; Wang CX
Int J Clin Pract Suppl; 2015 May; (183):43-52. PubMed ID: 26177348
[TBL] [Abstract][Full Text] [Related]
25. Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphism.
Durand P; Debray D; Kolaci M; Bouligand J; Furlan V; Fabre M; Letierce A; Verstuyft C; Becquemont L
Pharmacogenomics; 2013 Jul; 14(9):1017-25. PubMed ID: 23837476
[TBL] [Abstract][Full Text] [Related]
26. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation.
Ro H; Min SI; Yang J; Moon KC; Kim YS; Kim SJ; Ahn C; Ha J
Ther Drug Monit; 2012 Dec; 34(6):680-5. PubMed ID: 23149441
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms.
Miyata Y; Akamatsu N; Sugawara Y; Kaneko J; Yamamoto T; Suzuki H; Arita J; Sakamoto Y; Hasegawa K; Tamura S; Kokudo N
Ann Transplant; 2016 Aug; 21():491-9. PubMed ID: 27503662
[TBL] [Abstract][Full Text] [Related]
28. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
[TBL] [Abstract][Full Text] [Related]
29. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
30. Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients.
Buendía JA; Otamendi E; Kravetz MC; Cairo F; Ruf A; de Davila M; Powazniak Y; Nafissi J; Lazarowski A; Bramuglia G; Villamil F
Exp Clin Transplant; 2015 Oct; 13(5):441-8. PubMed ID: 26450467
[TBL] [Abstract][Full Text] [Related]
31. Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation.
Chen YK; Han LZ; Xue F; Shen CH; Lu J; Yang TH; Zhang JJ; Xia Q
PLoS One; 2014; 9(10):e109464. PubMed ID: 25310192
[TBL] [Abstract][Full Text] [Related]
32. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation.
Yang TH; Chen YK; Xue F; Han LZ; Shen CH; Zhou T; Luo Y; Zhang JJ; Xia Q
Int J Clin Pract Suppl; 2015 May; (183):53-62. PubMed ID: 26176181
[TBL] [Abstract][Full Text] [Related]
33. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
34. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Okuda M; Tanaka K; Inui K
Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
[TBL] [Abstract][Full Text] [Related]
35. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
36. Intravenous Administration of Tacrolimus Stabilizes Control of Blood Concentration Regardless of CYP3A5 Polymorphism in Living Donor Liver Transplantation: Comparison of Intravenous Infusion and Oral Administration in Early Postoperative Period.
Kato H; Usui M; Muraki Y; Okuda M; Nakatani K; Hayasaki A; Ito T; Iizawa Y; Murata Y; Tanemura A; Kuriyama N; Azumi Y; Kishiwada M; Mizuno S; Sakurai H; Isaji S
Transplant Proc; 2018 Nov; 50(9):2684-2689. PubMed ID: 30401377
[TBL] [Abstract][Full Text] [Related]
37. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
38. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
[TBL] [Abstract][Full Text] [Related]
39. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Tacrolimus Starting Doses Based on CYP3A5 Phenotype or Genotype in Kidney Transplant Recipients.
Largeau B; Guellec CB; Longuet H; Lesne P; Bouvarel A; Préteseille L; Marquet P; Halimi JM; Büchler M; Gatault P; Noble J
Prog Transplant; 2019 Dec; 29(4):300-308. PubMed ID: 31514576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
